Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 1.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,087 shares of the company’s stock after selling 2,931 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.23% of Immunome worth $1,976,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IMNM. Charles Schwab Investment Management Inc. boosted its position in Immunome by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company’s stock worth $4,856,000 after acquiring an additional 14,775 shares during the period. Three Bridge Wealth Advisors LLC bought a new stake in shares of Immunome in the 4th quarter worth $293,000. JPMorgan Chase & Co. raised its position in shares of Immunome by 2,540.4% during the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after purchasing an additional 624,045 shares during the period. MetLife Investment Management LLC raised its position in shares of Immunome by 17.7% during the fourth quarter. MetLife Investment Management LLC now owns 35,619 shares of the company’s stock worth $378,000 after purchasing an additional 5,354 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of Immunome by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 26,207 shares of the company’s stock valued at $278,000 after buying an additional 8,190 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stephens reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective on the stock. Lake Street Capital initiated coverage on Immunome in a research note on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price for the company. Wedbush restated an “outperform” rating and set a $21.00 target price (down previously from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Finally, Guggenheim reduced their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Insider Activity at Immunome

In related news, CTO Philip Tsai acquired 12,300 shares of the company’s stock in a transaction on Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, with a total value of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. The trade was a 58.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Clay B. Siegall acquired 137,100 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This represents a 20.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 161,400 shares of company stock valued at $1,207,395. Insiders own 8.60% of the company’s stock.

Immunome Stock Up 2.2%

IMNM stock opened at $9.26 on Wednesday. The company has a market cap of $805.73 million, a P/E ratio of -1.14 and a beta of 2.00. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $16.81. The business has a fifty day moving average of $7.73 and a 200-day moving average of $9.51.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. The business had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $0.46 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, equities research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.